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Abstract
Background: Reliable biomarkers of frontotemporal dementia (FTD) are currently lacking. FTD may be associated
with chronic immune dysfunction, microglial activation and raised inflammatory markers, particularly in progranulin
(GRN) mutation carriers. Levels of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) are elevated in
Alzheimer’s disease (AD), but they have not been fully explored in FTD.
Methods: We investigated whether cerebrospinal fluid (CSF) sTREM2 levels differ between FTD and controls, across
different clinical and genetic subtypes of FTD, or between individuals with FTD due to AD versus non-AD
pathology (based on CSF neurodegenerative biomarkers). We also assessed relationships between CSF sTREM2 and
other CSF biomarkers (total tau [T-tau], tau phosphorylated at position threonine-181 [P-tau] and β-amyloid 1–42
[Aβ42]) and age and disease duration. Biomarker levels were measured using immunoassays in 17 healthy controls
and 64 patients with FTD (behavioural variant FTD, n = 20; primary progressive aphasia, n = 44). Ten of 64 had
familial FTD, with mutations in GRN (n = 3), MAPT (n = 4), or C9orf72 (n = 3). Fifteen of 64 had neurodegenerative
biomarkers consistent with AD pathology (11 of whom had logopenic variant PPA). Levels were compared using
multivariable linear regressions.
Results: CSF sTREM2 levels did not differ between FTD and controls or between clinical subgroups. However,
GRN mutation carriers had higher levels than controls (mean ([SD] = 9.7 [2.9] vs. 6.8 [1.6] ng/ml; P = 0.028) and
MAPT (3.9 [1.5] ng/ml; P = 0.003] or C9orf72 [4.6 [1.8] ng/ml; P = 0.006) mutation carriers. Individuals with AD-like
CSF had higher sTREM2 levels than those with non-AD-like CSF (9.0 [3.6] vs. 6.9 [3.0] ng/ml; P = 0.029). CSF
sTREM2 levels were associated with T-tau levels in control and FTD groups and also with P-tau in those with FTD
and AD-like CSF. CSF sTREM2 levels were influenced by both age and disease duration in FTD.
Conclusions: Although CSF sTREM2 levels are not raised in FTD overall or in a particular clinical subtype of FTD,
levels are raised in familial FTD associated with GRN mutations and in FTD syndromes due to AD pathology.
Because CSF sTREM2 levels correlate with a marker of neuronal injury (T-tau), sTREM2 should be explored as a
biomarker of disease intensity in future longitudinal studies of FTD.
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Background
Frontotemporal dementia (FTD) is a common cause
of early-onset dementia, presenting with behavioural
change (behavioural variant FTD [bvFTD]) or lan-
guage impairment (primary progressive aphasia
[PPA]). Around one-third of cases are familial, associ-
ated most commonly with mutations in progranulin
(GRN), microtubule-associated protein tau (MAPT) or
chromosome 9 open reading frame 72 (C9orf72) [1].
Pathologically, the majority of individuals have fronto-
temporal lobar degeneration (FTLD) with inclusions
containing tau or transactive response DNA binding
protein 43 (TDP-43), although some, particularly
those with the logopenic variant of PPA (lvPPA), have
Alzheimer’s disease (AD) pathology [2]. Reliable bio-
markers that differentiate the pathological changes
underlying sporadic FTD in vivo or that predict dis-
ease onset, severity or progression in sporadic and fa-
milial FTD are currently lacking. There is growing
evidence that neuroinflammation and microglial dys-
function play a role in FTD, particularly in familial
FTD secondary to GRN mutations [3, 4]. Inflamma-
tory markers are variably altered in blood or cerebro-
spinal fluid (CSF) of patients with neurodegenerative
disease, including across the clinical, genetic and
pathological spectrum of FTD, and they could be use-
ful as disease biomarkers in future clinical trials.
The protein triggering receptor expressed on myeloid
cells 2 (TREM2) is an innate immune receptor expressed
on microglia and on myeloid cells outside the brain [5, 6].
TREM2 is upregulated on activated microglia and in-
volved in microglial phagocytosis [7–11], survival [12] and
chemotaxis and response to neuronal injury [13]. Homo-
zygous TREM2 mutations lead to a rare syndrome called
Nasu-Hakola disease [14], which is associated with an
early-onset FTD-like dementia, and homozygous TREM2
variants are associated with FTD-like syndromes without
bony involvement [15–18]. TREM2 undergoes cleavage of
its ectodomain to release a soluble TREM2 (sTREM2)
fragment into the extracellular space [9], which is measur-
able in CSF and blood. Although raised CSF sTREM2
levels were initially described in neuroinflammatory con-
ditions such as multiple sclerosis [19, 20], establishing the
relationship between sTREM2 and other markers of dis-
ease has recently become of great interest in neurodegen-
erative disorders.
Most studies of CSF sTREM2 levels in dementia have
focused on AD, but non-stratified patient cohorts have
produced conflicting results, including increased [21, 22],
reduced [9] or similar [23] levels in patients with AD com-
pared with healthy controls. However, CSF sTREM2 levels
may change according to disease stage in AD, with raised
levels in mild cognitive impairment and early sporadic
[24, 25] or pre-symptomatic familial [26] disease, but
lower levels (similar to controls) in established disease
[26]. This suggests that sTREM2 levels could be useful in
tracking the disease course in AD or for determining
proximity to disease onset in pre-symptomatic familial
cases, and this may also be the case for other neurodegen-
erative diseases, such as FTD. CSF sTREM2 levels correl-
ate with CSF levels of total tau (T-tau), a marker of
neuronal injury, in AD cohorts, but generally not with
β-amyloid 1–42 (Aβ42) levels [21, 22, 24–26]. This sug-
gests that CSF sTREM2 may be a useful marker of micro-
glial activation in response to neuronal injury, regardless
of amyloid pathology, and hence worth exploring in FTD.
Previous studies of CSF sTREM2 levels in FTD have
included small numbers of patients with undefined clin-
ical subtypes and have found widely differing results, in-
cluding lower [9], higher [22] or similar [21] levels in
patients with FTD compared with healthy controls. It re-
mains unclear whether CSF sTREM2 levels are altered
in FTD or whether they differ between the various clin-
ical subtypes of FTD. To our knowledge, no studies have
compared CSF sTREM2 levels across groups of individ-
uals with familial FTD to determine whether levels differ
between the genetic subtypes of FTD. In addition, indi-
viduals may develop clinical syndromes consistent with
FTD (bvFTD or PPA) due to underlying AD, rather than
FTLD, pathology. It is unclear whether CSF sTREM2
levels differ in patients with similar clinical syndromes
but contrasting pathologies.
Given the heterogeneous clinical, genetic and
pathological nature of FTD and the urgent need for
disease biomarkers, in this study we aimed to exam-
ine how CSF sTREM2 levels vary within a
well-phenotyped cohort of symptomatic individuals
with different clinical and genetic subtypes of FTD.
We also aimed to clarify how CSF sTREM2 levels
differ between individuals with clinical FTD syn-
dromes due to AD versus FTLD pathology (as deter-
mined by their CSF neurodegenerative biomarker
profile), as well as to establish whether sTREM2
levels correlate with levels of other CSF biomarkers
previously explored in AD: T-tau, tau phosphorylated
at position threonine 181 (P-tau) and Aβ42.
Methods
Participants
The cohort consisted of 64 individuals with dementia
consistent with FTD who met consensus diagnostic cri-
teria for either bvFTD [27] or PPA [28] and 17 cogni-
tively normal controls. Individuals with dementia were
recruited from the Specialist Cognitive Disorders Clinic
at the National Hospital for Neurology and Neurosur-
gery, London, UK, or from the University College
London (UCL) FTD cohort studies. Control partici-
pants were individuals with normal cognitive testing
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scores, normal neurological examinations and no
underlying neurological conditions, recruited from co-
hort studies at UCL. Among the 64 individuals with
FTD, there were 5 clinical subgroups: 20 had bvFTD,
16 non-fluent variant PPA (nfvPPA), 11 semantic vari-
ant PPA (svPPA), 14 lvPPA and 3 a PPA syndrome not
otherwise specified (PPA-NOS; not fulfilling criteria of
any of the other PPA phenotypes). All participants with
FTD were genetically screened for all known FTD
causative mutations, including the C9orf72 expansion.
Ten individuals had familial FTD, producing three gen-
etic subgroups, due to mutations in GRN (n = 3),
MAPT (n = 4) or C9orf72 (n = 3). All familial cases had
a clinical syndrome of bvFTD, except two individuals
with GRN mutations who had nfvPPA. Demographics
of the cohort are displayed in Table 1. Disease duration
was calculated as the time, in years, between age at
clinical onset of symptoms and date of CSF collection.
There was no difference in age at CSF collection
between the dementia and control groups overall
(mean difference − 0.87 years, unpaired t test: 95%
CI − 4.41 to 2.67; P = 0.628), but the svPPA subgroup
was younger than the nfvPPA subgroup (mean dif-
ference − 6.1 years, analysis of variance: 95% CI −
11.06 to − 1.13; P = 0.017) and lvPPA subgroup
(mean difference − 5.7 years, 95% CI − 10.8 to − 0.6;
P = 0.03). There was no significant difference in age
between any of the genetic subgroups or compared with
controls. There was a higher proportion of males in the
dementia group than in the control group (70.3% vs.
54.5%; χ2 = 7.06, df = 1, P = 0.008) and a higher proportion
of males in the bvFTD subgroup versus all other clinical
subgroups and controls (χ2 = 17.5; df = 5, P = 0.004), other
than the PPA-NOS group, in which all three participants
were male (Table 1). There was no significant difference in
disease duration between any of the clinical subgroups
(Kruskal-Wallis test; P > 0.05).
CSF collection, processing and biomarker analysis
For all participants, CSF was collected and stored using
standardised procedures [29]. Briefly, samples were col-
lected by lumbar puncture in polypropylene tubes,
which were immediately transferred to the laboratory.
Samples were centrifuged, and the supernatant was
aliquoted and stored at − 80 °C within 30 minutes of
arrival. CSF levels of T-tau, P-tau and Aβ42 were mea-
sured using commercially available INNOTEST sand-
wich enzyme-linked immunosorbent assays (Fujirebio
Europe, Gent, Belgium).
CSF sTREM2 immunoassay
CSF samples were analysed using an immunoassay
protocol adapted from one published previously [9].
Streptavidin-coated 96-well plates (Meso Scale Discovery
[MSD], Rockville, MD, USA) were blocked overnight at
4 °C in blocking buffer (0.5% bovine serum albumin
[BSA] and 0.05% Tween 20 in PBS, pH 7.4). The plates
were then incubated with the biotinylated polyclonal
goat anti-human TREM2 capture antibody (0.25 μg/ml,
BAF1828; R&D Systems, Minneapolis, MN, USA) di-
luted in blocking buffer, shaking for 1 hour at room
temperature. They were subsequently washed five times
with wash buffer (0.05% Tween 20 in PBS) and incu-
bated for 2 hours shaking at room temperature with
50 μl per well of either (1) the standard curve con-
structed from recombinant human TREM2 protein
(11084-H08H-50; Sino Biological Inc., Beijing, China) di-
luted in assay buffer (0.25% BSA and 0.05% Tween 20 in
PBS, pH 7.4) to produce concentrations ranging between
4000 pg/ml and 62.5 pg/ml or (2) CSF samples diluted
1:4 in assay buffer. Standards and CSF samples were
assayed in duplicate. Plates were again washed five times
with wash buffer before incubation for 1 hour shaking at
room temperature with the detection antibody, mono-
clonal mouse anti-human TREM2 antibody (1 μg/ml,
Table 1 Demographics and cerebrospinal fluid biomarker levels of control and dementia groups and all clinical subgroups
Control Dementia bvFTD nfvPPA svPPA lvPPA PPA-NOS
No. of subjects 17 64 20 16 11 14 3
Male sex, n (% group) 6 (54.5) 45 (70.3) 19 (95.0) 9 (56.2) 7 (63.6) 7 (50.0) 3 (100.0)
Age at CSF collection, years, mean (SD) 63.7 (6.4) 64.6 (6.5) 63.4 (7.1) 66.9 (5.9) 60.8 (6.0) 66.5 (6.0) 64.6 (5.4)
Age at onset, years, mean (SD) n/a 59.5 (6.9) 56.1 (6.7) 62.7 (6.1) 56.1 (5.3) 63.0 (6.7) 61.3 (4.1)
Disease duration at CSF collection,
years, mean (SD); median (IQR)
n/a 5.1 (3.8); 4.2
(2.7–6.3)
7.4 (5.6); 6.3
(3.4–8.8)
4.2 (1.9); 4.2
(2.8–5.1)
4.7 (2.1); 4.6
(3.4–6.3)
3.5 (2.0); 3.1
(1.9–4.8)
3.2 (1.3); 2.7
(2.3–4.7)
CSF sTREM2, ng/ml, mean (SD) 6.8 (1.6) 7.4 (3.2) 6.3 (3.7) 7.8 (2.2) 7.4 (2.4) 8.2 (4.1) 8.7 (1.9)
CSF Aβ42, pg/ml, mean (SD) 1032.2 (214.3) 758.1 (280.7) 828.3 (171.7) 842.5 (298.0) 894.0 (247.4) 444.6 (148.3) 804.3 (434.2)
CSF T-tau, pg/ml, mean (SD) 332.6 (82.4) 531.4 (404.5) 351.9 (135.5) 490.6 (247.8) 395.5 (200.3) 968.8 (617.0) 403.3 (208.5)
CSF P-tau, pg/ml, mean (SD) 52.7 (10.6) 57.0 (30.6) 45.7 (17.0) 50.6 (18.1) 44.9 (19.8) 91.7 (41.6) 49.0 (14.4)
CSF T-tau/Aβ42 ratio, median (IQR) 0.3 (0.2–0.5) 0.5 (0.3–1.0) 0.4 (0.3–0.5) 0.6 (0.3–0.9) 0.4 (0.3–0.5) 2.0 (1.1–3.2) 0.4 (0.2–1.2)
n/a Not applicable; for others, see list of abbreviations
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[B-3]: sc373828; Santa Cruz Biotechnology, Dallas, TX,
USA), diluted in blocking buffer. After five additional
washing steps, plates were incubated with the secondary
antibody (SULFO-TAG-labelled goat anti-mouse second-
ary antibody, R32AC-5; MSD) and incubated shaking for
1 hour in the dark. Last, plates were washed three times
with washing buffer, then twice in PBS alone. The elec-
trochemical signal was developed by adding MSD read
buffer T 4× (R92TC-2; MSD) diluted 1:2, and the light
emission was measured using the MSD Sector Imager
6000. The concentration of sTREM2 was calculated
using a five-parameter logistic curve-fitting method with
the MSD Workbench software package. Intra-assay coef-
ficients of variation were less than 10%, and all samples
were measured on the same day by a single operator
using the same reagents.
CSF AD biomarker classification
To examine whether CSF sTREM2 levels differ accord-
ing to the underlying pathology in FTD, rather than by
clinical syndrome, we used individuals’ CSF neurode-
generative biomarker profiles of T-tau and Aβ42
(Table 1) to classify all individuals with dementia into
two pathological subgroups (AD biomarker-positive
and AD biomarker-negative) based on whether there
was a CSF biomarker profile consistent with AD
(Table 2). We used a conservative cut-off of CSF T-tau/
Aβ42 ratio > 1.0 as being consistent with dementia sec-
ondary to AD pathology, based on a previous study
[29], and healthy controls were used as a comparison
for both groups (all 17 controls had a CSF T-tau/Aβ42
ratio < 1.0). The AD biomarker-positive dementia sub-
group consisted of 15 individuals with dementia, with a
CSF T-tau/Aβ42 ratio > 1.0. As expected, the majority
of these had lvPPA (n = 11); other diagnoses were
nfvPPA (n = 2), svPPA (n = 1) and PPA-NOS (n = 1). The
AD biomarker-negative subgroup contained the remaining
49 individuals with dementia with a CSF T-tau/Aβ42 ratio
< 1.0. No significant difference in age at CSF was seen be-
tween the two biomarker subgroups and controls, but me-
dian disease duration at CSF was shorter in the AD
biomarker-positive subgroup than in the AD
biomarker-negative subgroup (2.9 versus 4.6 years;
Mann-Whitney U test: P = 0.037). There were signifi-
cantly more males in the AD biomarker-negative sub-
group (73.4%) than in controls (54.5%) and the AD
biomarker-positive (60.0%) subgroup (χ2 = 7.9, df = 2,
P = 0.019).
Statistical analysis
CSF sTREM2 levels were first compared between the de-
mentia group (all individuals with FTD, both bvFTD and
PPA) and controls. The following subgroups were also
compared: (1) clinical subgroups (bvFTD, nfvPPA,
svPPA, lvPPA, PPA-NOS) with controls and between
each subgroup; (2) genetic subgroups (GRN, MAPT,
C9orf72) with controls and between each subgroup; and
(3) pathological subgroups (AD biomarker-positive de-
mentia and AD biomarker-negative dementia) compared
with each other and with controls. We also examined as-
sociations between CSF sTREM2 levels and CSF T-tau,
P-tau and Aβ42 levels in each group and subgroup. In
addition, we determined whether CSF sTREM2 levels
differed according to sex or were associated with other
parameters that may influence biomarker levels (age and
disease duration at CSF) in each group and subgroup.
This guided adjustment for these variables in group and
subgroup analyses. Associations of sTREM2 levels with
age, disease duration and biomarker levels, and sex dif-
ferences in sTREM2 levels, were not assessed within
Table 2 Demographics and cerebrospinal fluid biomarker levels of control group and cerebrospinal fluid Alzheimer’s disease
biomarker-defined subgroups with dementia
Control AD biomarker-negative dementia
(CSF T-tau/Aβ42 < 1.0)
AD biomarker-positive dementia
(CSF T-tau/Aβ42 > 1.0)
No. of subjects 17 49 15
Male sex, n (% group) 6 (54.5) 36 (73.4) 9 (60.0)
Age at CSF, years, mean (SD) 63.7 (6.4) 64.1 (6.7) 65.9 (6.0)
Age at onset, years, mean (SD) n/a 58.6 (6.8) 62.4 (6.7)
Disease duration at CSF collection, years,
mean (SD); median (IQR)
n/a 5.6 (4.1); 4.6 (3.1–6.6) 3.5 (2.1); 2.9 (1.7–5.1)
CSF sTREM2, ng/ml, mean (SD) 6.8 (1.6) 6.9 (3.0) 9.0 (3.6)
CSF Aβ42, pg/ml, mean (SD) 1032.2 (214.3) 833.9 (265.4) 510.5 (165.7)
CSF T-tau, pg/ml, mean (SD) 332.6 (82.4) 373.5 (173.0) 1047.2 (511.3)
CSF P-tau, pg/ml, mean (SD) 52.7 (10.6) 44.8 (15.3) 97.0 (34.3)
CSF T-tau/Aβ42 ratio, median (IQR) 0.3 (0.2–0.5) 0.4 (0.3–0.7) 1.6 (1.2–3.2)
AD Alzheimer’s disease, n/a Not applicable; for others, see list of abbreviations
The dementia subgroups include individuals with FTD (bvFTD and PPA) defined by their CSF biomarker profile as stated
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individual genetic subgroups, owing to small group size.
All analyses were carried out using STATA14
(StataCorp, College Station, TX, USA), with a signifi-
cance threshold of P < 0.05. Shapiro-Wilk tests were
used to test assumptions of normality for all parameters.
Assessment of residuals in multivariable linear regres-
sion analyses of sTREM2 across groups revealed that
these were normally distributed and so met the assump-
tions required for parametric linear regression analysis.
Multivariable linear regressions were used to compare
CSF sTREM2 levels between groups and subgroups,
adjusting for age and sex in all analyses, and also for dis-
ease duration in analyses involving comparison of dis-
ease subgroups. Multivariable linear regressions were
also used to investigate the association between sTREM2
levels and levels of CSF T-tau, P-tau and Aβ42 for each
individual group and subgroup. These regressions were
adjusted for age at CSF and sex (for the control group)
and for age at CSF, sex and disease duration (for demen-
tia and all subgroups). CSF sTREM2 levels (rather than
the residuals of CSF sTREM2 levels as examined for re-
gression analyses) were not normally distributed, so the
Mann-Whitney U test was used to compare sTREM2
levels between males and females across the whole co-
hort and within each group and subgroup. Multivariable
linear regression models were also used to assess associ-
ations between sTREM2 and age at CSF (adjusted for
sex in the control group and both sex and disease dur-
ation in the dementia group and all subgroups) and dis-
ease duration at CSF (for dementia and all subgroups,
adjusted for age and sex). Interactions between subgroup
and age at CSF collection or disease duration were in-
cluded for subgroup analyses to examine whether these
associations differed by disease subgroup.
Results
CSF sTREM2 levels do not differ between FTD and
controls or between clinical subtypes of FTD
CSF sTREM2 levels did not significantly differ between in-
dividuals with dementia consistent with FTD (combined
bvFTD and PPA) and controls (mean [SD] = 7.4 [3.2] ver-
sus 6.8 [1.6] ng/ml; P = 0.431) (Fig. 1a) or between any of
the clinical subgroups and controls, adjusting for age and
sex, or between any of the clinical subgroups, adjusting
for age, sex and disease duration (Fig. 1b, Table 3). CSF
sTREM2 values for control and dementia groups and for
each clinical subgroup are summarised in Table 1.
Detailed results of regression analyses comparing all
groups and subgroups are presented in Table 3.
CSF sTREM2 levels are higher in GRN mutation carriers
There was a significant difference in sTREM2 levels
across the genetic subgroups (F3,21 = 4.40, P = 0.015)
(Fig. 1c, Table 3), adjusting for age and sex. The GRN
mutation subgroup had higher levels than controls
(mean [SD] = 9.7 [2.9] versus 6.8 [1.6] ng/ml; P = 0.028),
and also than the MAPT (3.9 [1.5] ng/ml; P = 0.003) and
C9orf72 mutation (4.6 [1.8] ng/ml; P = 0.006) subgroups.
There was no significant difference between other gen-
etic subgroups or between MAPT or C9orf72 subgroups
and controls (Fig. 1c, Table 3).
CSF sTREM2 levels are higher in FTD associated with AD
pathology
In the pathological subgroup analysis, there was a
trend towards a difference in CSF sTREM2 levels be-
tween the three groups (F2,76 = 2.55, P = 0.085), adjust-
ing for age and sex. Levels were highest in the AD
biomarker-positive dementia group (mean [SD] = 9.0
[3.6] ng/ml) compared with the other two groups
(AD biomarker-negative dementia group = 6.9 [3.0]
ng/ml; controls = 6.8 [1.6] ng/ml) (Fig. 1d). There was
a significant difference in sTREM2 levels between the
two pathological subgroups, with higher sTREM2
levels in those with positive AD biomarkers than in
those with negative AD biomarkers (F2,58 = 3.77; P =
0.029), adjusting for age and sex. The difference in
CSF sTREM2 levels between these two subgroups was
affected by disease duration, with differences becom-
ing more obvious as disease duration increased
(Fig. 3c). A β value for the mean difference between
these two subgroups is not presented in Table 3, be-
cause it would not be representative of this varying
relationship. There was a trend towards higher levels
in the AD biomarker-positive subgroup compared
with controls (Fig. 1d), although this did not reach
significance (β = 1.92; P = 0.057), and there was no dif-
ference between the AD biomarker-negative subgroup
and controls (β = 0.183; P = 0.823).
Associations between CSF sTREM2 and CSF T-tau, P-tau
and Aβ42
Associations between CSF sTREM2 levels and levels of
CSF neurodegenerative biomarkers T-tau, P-tau and
Aβ42 differed according to clinical diagnosis and CSF
biomarker profile. In controls, CSF sTREM2 levels were
positively associated with CSF T-tau levels adjusting for
age and sex (β = 0.010, P = 0.033) (Fig. 2a), but not with
P-tau (β = 0.009, P = 0.825) (Fig. 2b) or Aβ42 (β = −
0.0001, P = 0.958) (Fig. 2c) levels. However, in the demen-
tia group, CSF sTREM2 levels were positively associated
with levels of all three markers, after adjusting for age, sex
and disease duration: T-tau (β = 0.003, P < 0.001) (Fig. 2a),
P-tau (β = 0.038, P = 0.002) (Fig. 2b) and Aβ42 (β = 0.003,
P = 0.033) (Fig. 2c). CSF sTREM2 levels were not associ-
ated with CSF T-tau, P-tau or Aβ42 in any of the clinical
subgroups, except for lvPPA (most of whom had CSF con-
sistent with AD), where they were positively associated
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with levels of all three markers: T-tau (β = 0.005, P <
0.001), P-tau (β = 0.075, P < 0.001) and Aβ42 (β =
0.015, P = 0.005). After stratifying the dementia
group by CSF AD biomarker profile, there was an
association between CSF sTREM2 and CSF T-tau in both
pathological subgroups (AD biomarker-negative: β =
0.004, P = 0.049; AD biomarker-positive: β = 0.005, P =
0.002) (Fig. 2d), adjusting for age, sex and disease duration.
There was also an association between sTREM2 and P-tau
levels in the AD biomarker-positive dementia subgroup (β
= 0.069, P = 0.004), but not in the AD biomarker-negative
subgroup (β = 0.028, P = 0.284) (Fig. 2e), and, in con-
trast, with Aβ42 levels in the AD biomarker-negative
subgroup (β = 0.005, P = 0.002), but not in the AD
biomarker-positive subgroup (β = 0.009, P = 0.083)
(Fig. 2f ).
CSF sTREM2 levels are influenced by age and disease
duration
CSF sTREM2 levels were positively associated with age at
CSF collection in the whole cohort (β = 0.165, P = 0.001)
(Fig. 3a) and in individuals with dementia (β = 0.189, P <
0.001) (Fig. 3a). In the control group, this association was
not significant (β = 0.061, P = 0.591) (Fig. 3a), but there
was no significant difference between the dementia and
control groups in the association between CSF sTREM2
levels and age (P = 0.312). In the clinical subgroup ana-
lysis, there was no significant difference between the coef-
ficients for age by clinical subgroup (P = 0.964), and after
adjusting for sex and disease duration, the association with
age was generally similar in the majority of subgroups
(Fig. 4a) (bvFTD β = 0.271, nfvPPA β = 0.184, svPPA β =
0.217, lvPPA β = 0.219, PPA-NOS β = 0.003), although this
a b
c d
Fig. 1 Comparison of CSF sTREM2 levels between groups and subgroups. Graphs show how CSF sTREM2 levels differ across (a) control and dementia
(overall FTD, containing bvFTD and PPA) groups; (b) controls and clinical subgroups; (c) controls and genetic subgroups; and (d) controls and CSF
biomarker-defined dementia subgroups (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive
dementia: CSF T-tau/Aβ42 ratio > 1.0. Horizontal bars show mean CSF sTREM2 levels and upper and lower 95% CIs for each group. *P < 0.05, **P < 0.01.
Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, C9orf72 Chromosome 9 open reading frame 72
gene, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, GRN Progranulin gene, lvPPA Logopenic variant primary progressive aphasia, MAPT
Microtubule-associated protein tau gene, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise
specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tau
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reached significance only for bvFTD (P = 0.017). In the
pathological subgroup analysis, CSF sTREM2 levels were
associated with age in both the AD biomarker-negative (β
= 0.185, P = 0.006) and AD biomarker-positive (β = 0.282,
P = 0.043) dementia subgroups. When we assessed inter-
actions between pathological subgroup and age, there was
no significant difference between the coefficients for age
by subgroup (P = 0.528).
CSF sTREM2 levels were negatively associated with dis-
ease duration in the dementia group (β =− 0.235, P = 0.025)
(Fig. 3b). In the clinical subgroup analysis, sTREM2 levels
were negatively associated with disease duration in bvFTD
(β = − 0.324, P = 0.014), but no significant association was
seen in other clinical subgroups (Fig. 4b). Despite consider-
able heterogeneity in the slopes, there was no significant
difference between the coefficients for disease duration by
clinical subgroup (P = 0.275). In the pathological subgroup
analysis, there was a significant difference in the coefficients
for disease duration between the two dementia subgroups
(P = 0.027). There was a significant negative association be-
tween CSF sTREM2 level and disease duration in the AD
biomarker-negative subgroup (β = − 0.253, P = 0.018) but a
trend towards a positive association in the AD biomarker
positive subgroup (β = 0.604, P = 0.106). This resulted in
Table 3 Comparisons of cerebrospinal fluid soluble TREM2 levels between all disease groups and subgroups and controls
Groups compared Mean (SEM) difference
in CSF sTREM2 (ng/ml)
95% CI for CSF
sTREM2 (ng/ml)
P value
Dementia vs. control 0.638 (0.806) −0.966, 2.244 0.431
Clinical subgroups
bvFTD vs. control −0.349 (1.035) −2.413, 1.713 0.736
nfvPPA vs. control 0.544 (1.009) −1.468, 2.556 0.592
svPPA vs. control 1.145 (1.129) −1.107, 3.397 0.314
lvPPA vs. control 1.040 (1.037) −1.025, 3.106 0.319
PPA-NOS vs. control 1.840 (1.837) −1.820, 5.502 0.320
nfvPPA vs. bvFTD 0.305 (1.153) −2.004, 2.615 0.792
svPPA vs. bvFTD 1.344 (1.190) −1.041, 3.729 0.264
lvPPA vs. bvFTD 0.723 (1.224) −1.730, 3.176 0.557
PPA-NOS vs. bvFTD 1.228 (1.927) −2.631, 5.088 0.526
svPPA vs. nfvPPA 1.038 (1.247) −1.460, 3.537 0.409
lvPPA vs. nfvPPA 0.417 (1.101) −1.789, 2.624 0.706
PPA-NOS vs. nfvPPA 0.922 (1.939) −2.961, 4.806 0.636
lvPPA vs. svPPA −0.621 (1.287) −3.199, 1.957 0.631
PPA-NOS vs. svPPA −0.116 (2.016) −4.154, 3.923 0.954
PPA-NOS vs. lvPPA 0.505 (1.967) −3.343, 4.445 0.798
Genetic subgroups
GRN vs. control 2.748 (1.161) 0.331, 5.163 0.028a
MAPT vs. control −2.230 (1.144) −4.609, 0.149 0.065
C9orf72 vs. control −1.897 (1.266) −4.529, 0.735 0.149
GRN vs. MAPT 4.978 (1.483) 1.893, 8.063 0.003a
GRN vs. C9orf72 4.644 (1.536) 1.448, 7.840 0.006a
C9orf72 vs. MAPT 0.334 (1.408) −2.595, 3.262 0.815
Pathological subgroups
AD biomarker-positive dementia vs. controls 1.921 (0.996) −0.062, 3.905 0.057
AD biomarker-negative dementia vs. controls 0.183 (0.817) −1.446, 1.812 0.823
AD biomarker-positive dementia vs. AD biomarker-negative dementia F(2,58) = 3.77, P = 0.029
a,b
See list of abbreviations for definition of abbreviations
Mean differences and 95% CIs are β values arising from multivariable linear regressions, adjusted for age and sex (disease groups and subgroups vs. controls),
or age, sex and disease duration (between disease groups or subgroups, except for between genetic subgroups, which were adjusted for age and sex).
Dementia group includes all individuals with FTD (bvFTD and PPA)
aSignificant at P < 0.05
bDifference between groups changes with varying disease duration; results of regression analysis comparing groups overall are presented, rather than specific
value for mean difference
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the difference in CSF sTREM2 levels between these two
subgroups increasing as disease duration increased
(Fig. 3c).
CSF sTREM2 levels did not differ by sex within the
whole cohort (median, males = 7.08 vs. females =
6.85 ng/ml; P = 0.992), or in controls, dementia, or any
of the clinical or pathological subgroups, apart from
in the svPPA subgroup, where males had higher
sTREM2 levels than females (median = 9.51 vs.
4.98 ng/ml; P = 0.023).
a d
b e
c f
Fig. 2 Relationship between CSF sTREM2 and CSF neurodegenerative biomarker levels. Graphs show associations between CSF sTREM2 and CSF
T-tau (a), P-tau (b) and Aβ42 (c) levels for control and dementia groups, and between CSF sTREM2 levels and CSF T-tau (d), P-tau (e) and Aβ42 (f)
levels for the control group and dementia subgroups defined by CSF biomarker status (pathological subgroups). AD biomarker-negative
dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Lines are group regression lines adjusted for
age and sex (controls) and age, sex and disease duration (overall dementia group and biomarker-defined dementia subgroups). See main text for
individual β and P values for each association. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, P-tau tau phosphorylated at
position threonine-181, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, T-tau Total tau
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Discussion
This study shows that CSF sTREM2 levels do not differ
overall between individuals with FTD and cognitively
normal controls or between the various clinical subtypes
of FTD. However, CSF sTREM2 levels are higher in
those with familial FTD due to GRN mutations, albeit
within a small cohort, and in individuals with a clinical
syndrome consistent with FTD but CSF biomarkers con-
sistent with underlying AD pathology. In addition, CSF
sTREM2 levels are positively associated with levels of
CSF T-tau in individuals with FTD and also with P-tau
in individuals with likely AD pathology, and they are in-
fluenced by both age and disease duration.
Using a well-phenotyped cohort, we were able to com-
pare CSF sTREM2 levels between individuals with FTD
and controls, and across a variety of more distinct,
clinically defined FTD syndromes, which, to our know-
ledge, has not been described previously. Other studies
have found significantly lower [9] or higher [22] CSF
sTREM2 levels in FTD than in controls. However, these
studies assessed a much smaller number of FTD cases
and without clearly defined clinical subgroups. There
was significant variability in sTREM2 levels within our
clinical subgroups, and large intergroup variability has
been noted in studies of AD, where the substantial over-
lap between levels in each group limited the utility of
sTREM2 to differentiate between AD and controls, des-
pite a higher level in the AD group overall [21, 26]. CSF
sTREM2 is also raised in a number of different neuroin-
flammatory [19, 20] and other neurodegenerative [21]
diseases, limiting its diagnostic specificity for FTD. How-
ever, given the negative association with disease duration
a
c
b
Fig. 3 Relationship between CSF sTREM2 levels and age and disease duration at CSF collection. Graphs show CSF sTREM2 versus age (a) and
disease duration (b and c) at CSF collection for the whole cohort (a, dotted line), dementia and control groups (a and b), and dementia
subgroups defined by CSF biomarker status (c). Lines in (a) are group regression lines adjusted for sex (whole cohort and controls) and sex and
disease duration (dementia group). Line in (b) is group regression line for dementia group adjusted for age and sex. Lines in (c) are group
regression lines adjusted for age and sex for each CSF biomarker-defined dementia subgroup. AD biomarker-negative dementia: CSF T-tau/Aβ42
ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. See main text for individual β and P values for each association. Aβ42
β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, CSF Cerebrospinal fluid, lvPPA Logopenic variant
primary progressive aphasia, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified,
sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tau
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in our study, there may be a differential profile of CSF
sTREM2 according to disease stage in FTD, as has been
identified in the continuum from mild cognitive impair-
ment to AD [24, 25], or according to disease intensity,
as has been identified for serum and CSF neurofilament
light chain levels in FTD [30, 31], which would be clinic-
ally useful.
We included a number of individuals with familial
FTD in our study, enabling an exploratory analysis of
differences in CSF sTREM2 between individuals with the
three most common mutations linked to FTD (GRN,
MAPT and C9orf72) and compared with cognitively nor-
mal controls. This adds to previous studies of raised in-
flammatory CSF markers in familial FTD, particularly in
GRN mutation carriers [32–34]. Although we were able
to include only a small number of individuals in each
mutation group, we found that individuals with FTD
due to GRN mutations had higher CSF sTREM2 levels
than those with MAPT or C9orf72 mutations, and com-
pared with controls. This may be due to a link between
GRN and TREM2, both of which are expressed by
microglia, and thought to regulate microglial function
and immune pathways in general. GRN-knockout mice
have upregulated TREM2 gene expression [3, 35] and
excessive synaptic pruning mediated by aberrantly acti-
vated microglia [3]. sTREM2 promotes release of inflam-
matory cytokines and enhanced microglial activation
and survival in mice [36]. Mouse models of homozygous
GRN mutations and patients with heterozygous GRN
mutations display excessive microglial activation on
post-mortem brain tissue analysis [3, 37–40] and dysreg-
ulated levels of other inflammatory markers [32–34, 41].
Increased microglial activation in the context of GRN
haploinsufficiency could lead to enhanced TREM2 ex-
pression by microglia, increasing release of sTREM2 into
the CSF and promoting survival of dysfunctional micro-
glia or exacerbating neuronal damage through excessive
phagocytosis.
Although downregulating TREM2 expression or redu-
cing CSF sTREM2 levels could be a therapeutic target for
individuals with FTD secondary to GRN mutations, ani-
mal models of multiple sclerosis deteriorated with TREM2
inhibition [42]. In addition, the homozygous TREM2 mu-
tations that cause the frontal lobe dementia associated
with Nasu-Hakola disease impair TREM2 function, lock-
ing microglia in a homeostatic, rather than phagocytic,
state [10] and produce very low CSF sTREM2 levels [9].
This suggests that TREM2 may be protective in some
circumstances. There is clearly a fine balance between
TREM2 activity and suppression. However, CSF sTREM2
levels could rise in pre-symptomatic GRN mutation car-
riers before symptom onset and act as a useful marker of
disease proximity, as in familial AD [26].
Because several studies have shown higher CSF sTREM2
levels in amnestic AD than in controls [21, 22, 24], we
hypothesised that individuals with a clinical diagnosis of
an FTD syndrome (i.e., bvFTD or PPA) but underlying
AD pathology would have higher sTREM2 levels than
controls. We were also keen to establish whether sTREM2
levels differ by underlying pathology (AD versus FTLD) in
those with FTD. This is of particular use in the FTD field
because certain patients, particularly those with lvPPA,
may have underlying AD pathology and differing relation-
ships between CSF sTREM2 and other disease biomarkers
a b
Fig. 4 Relationship between CSF sTREM2 levels and age and disease duration at CSF collection in clinical subtypes of FTD. Graphs show CSF
sTREM2 versus age (a) and disease duration (b) at CSF collection for each clinical subgroup. Lines in (a) are group regression lines adjusted for
sex and disease duration; lines in (b) are group regression lines adjusted for age and sex. See main text for individual β and P values for each
association. bvFTD Behavioural variant frontotemporal dementia, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, lvPPA Logopenic variant
primary progressive aphasia, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified,
sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia
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compared with individuals with FTLD, which could
prove an issue for future clinical trials. By stratifying in-
dividuals with FTD by their CSF neurodegenerative
biomarker profile (into AD biomarker-positive and AD
biomarker-negative groups), we were able compare CSF
sTREM2 levels (and relationships with other bio-
markers) between biochemically defined, rather than
clinically defined, syndromes. The significantly higher
CSF sTREM2 levels in individuals with FTD but
AD-like CSF (AD biomarker-positive group) than in
those with non-AD-like CSF (AD biomarker-negative
group), who most likely have FTLD, in our study sug-
gests that individuals with significant neuronal injury
due to AD (combined tau and amyloid pathology) may
have more microglial activation and sTREM2 release
into the CSF than those with FTLD. This is supported
by our finding that CSF sTREM2 levels did not signifi-
cantly differ between individuals with FTD and
non-AD-like CSF and controls. There was a trend to-
wards higher CSF sTREM2 levels in those with FTD
and AD-like CSF than controls, although this did not
reach significance, perhaps due to small group size.
Interestingly, the difference in CSF sTREM2 levels be-
tween individuals with likely underlying AD versus
FTLD became more pronounced with increasing dis-
ease duration. This most likely occurred because CSF
sTREM2 levels were negatively associated with disease
duration in those with FTLD, and there was a trend to-
wards a positive association with disease duration in
those with AD. In individuals with FTLD, microglial ac-
tivation could decrease more over time, leading to a
gradual decline in CSF sTREM2 levels. Alternatively,
this separation may have occurred because several indi-
viduals with FTD and non-AD-like CSF had much lon-
ger disease durations (perhaps due to a less intense
disease process) and much lower sTREM2 levels than
the majority of those with AD-like CSF. Longitudinal
CSF data from both groups are required to examine
this further.
We went on to explore the relationship between levels
of CSF sTREM2 and validated neurodegenerative bio-
markers that reflect neuronal injury (T-tau), hyperpho-
sphorylated tau (P-tau) and amyloid pathology (Aβ42).
In individuals with FTD but likely AD pathology, higher
CSF sTREM2 levels were associated with higher CSF
T-tau and P-tau levels. This is consistent with associa-
tions between CSF sTREM2 and T-tau and/or P-tau
levels in amnestic AD [21, 24, 25], as well as in our
lvPPA subgroup, the majority of whom had AD-like
CSF. We found that CSF sTREM2 levels were associated
with T-tau (but not P-tau) levels in those with FTD due
to likely FTLD, consistent with the theory that sTREM2
levels may also rise in the context of neuronal injury
without concurrent hyperphosphorylated tau or amyloid
pathology [22, 24–26]. In our control group, higher CSF
sTREM2 levels were associated with higher CSF T-tau
levels, but not with P-tau or Aβ42. Other studies have
found associations with levels of T-tau, P-tau, or all
three markers (T-tau, P-tau and Aβ42) in healthy con-
trols [23–26]. This may reflect differential effects of
microglial activation in response to mild age-related
neuronal injury between individual cohorts, the variabil-
ity of CSF T-tau and P-tau levels in healthy ageing [43,
44], or the variety of control group age distributions
across studies. Surprisingly, we found a small but signifi-
cant positive association between CSF sTREM2 and
Aβ42 levels in FTD overall and in those with FTD and
likely FTLD (rather than AD) pathology. This associ-
ation with Aβ42 was observed in the control groups of
three other studies [23–25], one of which speculated
that the positive correlation between sTREM2 and Aβ42
levels was due to very early pre-symptomatic AD in
some control individuals, because CSF Aβ42 may transi-
ently increase due to reduced clearance before it de-
creases [23]. The positive association in our overall FTD
group likely reflects that some individuals in this group
were in a different stage of the AD pathology continuum
than others, particularly because it included individuals
with lvPPA. It remains unclear why there was also a
positive association with Aβ42 in individuals with likely
FTLD, although there may well be reduced clearance of
amyloid in the context of extensive other pathology.
However, overall in FTD there appears to be more of an
association between CSF sTREM2 and T-tau and P-tau
levels, than with Aβ42 levels, suggestive of a stronger
link between sTREM2 and neuronal injury, than amyloid
pathology itself. This is consistent with previous studies
in AD [21–26].
We also examined relationships between sTREM2 levels
and relevant clinical parameters such as age, disease dur-
ation and sex, which may affect TREM2 expression. The
positive association between CSF sTREM2 levels and age
in FTD is consistent with studies of AD [22–25]. Increased
microglial activity associated with ageing leads to increased
microglial TREM2 expression in healthy individuals [45]
and in AD [46], and this could also be the case in FTD.
We did not find a significant association with age in con-
trols, as has been found previously [23, 25], perhaps be-
cause our control group was generally younger (to match
to the FTD group) and smaller than those in other studies.
Other studies’ control groups had a broader age range and
so may have included some older, cognitively normal indi-
viduals with early AD pathology (and higher sTREM2
levels), leading to an apparently positive association be-
tween sTREM2 levels and age. We would suggest that fu-
ture studies of CSF sTREM2 levels in neurodegenerative
disease cohorts explore associations with age and consider
adjusting group analyses for age at CSF collection.
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Because previous research has shown that CSF
sTREM2 levels vary by disease stage in mild cognitive
impairment and AD [24, 25], we examined the relation-
ship between CSF sTREM2 levels and disease duration
in FTD. CSF sTREM2 levels were negatively associated
with disease duration in FTD overall and particularly in
bvFTD, where the widest range of disease durations was
present. In the early stages of FTD, CSF sTREM2 levels
may be high (due to florid microglial activation in re-
sponse to incipient neurodegeneration), whereas later on
in disease, levels may decrease, perhaps as compensatory
microglial overactivation is overwhelmed by neurode-
generation. It has been postulated that this may occur in
AD, and CSF sTREM2 levels could therefore act as a
marker of disease progression [24]. An alternative ex-
planation for our findings is that CSF sTREM2 levels
may just be lower in individuals with FTD who have less
aggressive disease and hence longer disease durations.
CSF sTREM2 levels could therefore be a biomarker of
rate of neuronal injury and disease intensity in FTD, in
keeping with the positive association with CSF T-tau
levels in individuals with non-AD-like CSF, who most
likely have FTLD. Although the lack of longitudinal data
in our study precludes a conclusion that levels of CSF
sTREM2 rise and then fall over the disease course in
FTD, our findings emphasise the importance of future
studies assessing associations between CSF biomarker
levels and disease duration.
Although CSF sTREM2 levels did not differ by sex
within our whole cohort or in our dementia or control
groups, there was a difference in the svPPA subgroup,
with higher CSF sTREM2 levels in males. The majority
of studies focusing on AD have not found an association
between CSF sTREM2 levels and sex [21, 23–25],
although significantly higher levels [22] or a trend to-
wards higher levels [26] have been observed in males.
Although it remains unclear whether sex affects
sTREM2, we adjusted all analyses for sex.
A limitation of our study is that some of the FTD clin-
ical and genetic subgroups were rather small, which may
have limited our power to detect significant differences
between groups. However, this is inherent to a disease
such as FTD, where rarer subtypes exist, and it is diffi-
cult to avoid when analysing biomarker levels across a
broad clinical and pathological spectrum of disease and
when employing CSF collection and biomarker analysis
at one centre in order to minimise inter-centre variation.
Other studies with multi-centre CSF sources have shown
significant variability in sTREM2 levels between centres
[25], which we were keen to avoid. Our dementia group
contained individuals with a diagnosis of an FTD syn-
drome, including those typically associated with
FTLD-TDP or FTLD-tau (bvFTD, svPPA and nfvPPA)
and those associated with AD pathology (lvPPA), which
in theory could have differentially affected sTREM2
levels within the group as a whole. However, we were
able to dissect out any differences in sTREM2 linked to
differing pathologies through stratification of all patients
with dementia by their CSF biomarker profile. Although
most cases of dementia were not pathologically con-
firmed, all met recent diagnostic criteria for bvFTD [27]
or PPA [28], and our CSF ratio cut-off was intentionally
stringent to minimise misclassification of cases into the
wrong pathology subgroup. Our dementia group com-
bined individuals with a wide range of disease durations,
which we showed was independently associated with
sTREM2 levels. However, we adjusted analyses for dis-
ease duration wherever possible to account for this. We
did not include any individuals with mild cognitive im-
pairment, because this is typically a ‘pre-AD’ rather than
a ‘pre-FTD’ state, nor did we analyse longitudinal CSF
samples or samples from pre-symptomatic mutation car-
riers at risk of familial FTD. This means we cannot de-
finitively conclude whether CSF sTREM2 levels change
over the disease course, and therefore reflect disease
proximity, intensity or progression in FTD, or how
sTREM2 relates to changes in other CSF biomarkers
such as T-tau over time.
Conclusions
Although CSF sTREM2 does not seem useful for differen-
tiating between individuals with FTD and healthy con-
trols, or for delineating a particular clinical subtype of
FTD, levels are higher in familial FTD associated with
GRN mutations (albeit within a small preliminary cohort)
and in individuals with a clinical syndrome consistent with
FTD but underlying AD, rather than FTLD, pathology.
Because CSF sTREM2 levels correlate with a measure of
neuronal injury (T-tau), they may reflect disease intensity
in FTD, but this requires further exploration.
Future studies should analyse CSF sTREM2 levels
within larger cohorts of individuals with FTD, across a
variety of clearly defined clinical subgroups, and ideally in
pathologically confirmed cases. Inclusion of a larger num-
ber of familial FTD cases with mutations in GRN, MAPT
and C9orf72 (which have known pathology) would be
helpful in this regard and would enable confirmation of
our preliminary observations of higher levels in symptom-
atic GRN mutation carriers. Assessment of CSF sTREM2
levels in pre-symptomatic individuals at risk of familial
FTD could establish if and when levels change prior to ex-
pected symptom onset. This would help to elucidate
whether CSF sTREM2 levels may be useful as a biomarker
of disease proximity in FTD, which, if validated, may be
useful for guiding timely initiation of treatments or asses-
sing treatment response in clinical trials. This would
maximise the chance of benefitting individuals before
significant neurodegeneration occurs. Exploration of
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relationships between baseline and longitudinal measure-
ments of CSF sTREM2 levels and other markers of disease
intensity (such as serum or CSF neurofilament light levels
or frontal lobe atrophy rate) would also enable determin-
ation of whether CSF sTREM2 can be used as a biomarker
of disease intensity in sporadic or familial FTD.
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